Limitation of the activated partial thromboplastin time as a monitoring method of the direct thrombin inhibitor argatroban
暂无分享,去创建一个
[1] T. Trujillo,et al. Comparison of the aPTT with alternative tests for monitoring direct thrombin inhibitors in patient samples. , 2014, American journal of clinical pathology.
[2] C. Alaniz,et al. Apparent Argatroban Resistance in a Patient with Elevated Factor VIII Levels , 2013, The Annals of pharmacotherapy.
[3] W. Chandler,et al. Alternative Monitoring of Argatroban Using Plasma-Diluted Thrombin Time , 2013, The Annals of pharmacotherapy.
[4] H. Watson,et al. Guidelines on the diagnosis and management of heparin‐induced thrombocytopenia: second edition , 2012, British journal of haematology.
[5] D. van de Kerkhof,et al. Measuring direct thrombin inhibitors with routine and dedicated coagulation assays: which assay is helpful? , 2012, American journal of clinical pathology.
[6] A. Koster,et al. Results of a consensus meeting on the use of argatroban in patients with heparin-induced thrombocytopenia requiring antithrombotic therapy - a European Perspective. , 2012, Thrombosis research.
[7] Michael P Gulseth,et al. High-dose argatroban for treatment of heparin-induced thrombocytopenia with thrombosis: a case report and review of laboratory considerations. , 2012, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[8] A. Dans,et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.
[9] D. Zakalik,et al. Venous limb gangrene and fatal hemorrhage: Adverse consequences of hit “overdiagnosis” in a patient with antiphospholipid syndrome , 2011, American journal of hematology.
[10] C. Samama,et al. Argatroban and renal replacement therapy in a morbidly obese patient with heparin-induced thrombocytopenia: a case report. , 2010, Thrombosis research.
[11] W. Chandler,et al. Monitoring direct thrombin inhibitors with a plasma diluted thrombin time , 2007, Thrombosis and Haemostasis.
[12] Jörg Ingrid,et al. Treatment of Patients with a History of Heparin-Induced Thrombocytopenia and Anti-Lepirudin Antibodies with Argatroban , 2005, Journal of Thrombosis and Thrombolysis.
[13] J. Harenberg,et al. Collaborative study on monitoring methods to determine direct thrombin inhibitors lepirudin and argatroban , 2005, Journal of thrombosis and haemostasis : JTH.
[14] J. Francis,et al. Effect of argatroban on the activated partial thromboplastin time: a comparison of 21 commercial reagents , 2005, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[15] J. T. Owings,et al. Comparing Direct Thrombin Inhibitors Using aPTT, Ecarin Clotting Times, and Thrombin Inhibitor Management Testing , 2004, The Annals of pharmacotherapy.
[16] J. Kelton,et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. , 2003, Archives of internal medicine.
[17] J. Harenberg,et al. Monitoring of Anticoagulant Effects of Direct Thrombin Inhibitors , 2002, Seminars in thrombosis and hemostasis.
[18] S. Swan,et al. Comparison of Anticoagulant Effects and Safety of Argatroban and Heparin in Healthy Subjects , 2000, Pharmacotherapy.
[19] D. Hoppensteadt,et al. Pharmacokinetics and Pharmacodynamics of Argatroban as Studied by HPLC and Functional Methods: Implications in the Monitoring and Dosage-Optimizations in Cardiovascular Patients , 1998 .
[20] G. Wolf,et al. Comparison of the ecarin chromogenic assay and different aPTT assays for the measurement of argatroban concentrations in plasma from healthy individuals and from coagulation factor deficient patients. , 2008, Thrombosis research.